Conference Activities & Talks -

Division display  41 - 60 of about 155 ／  All the affair displays >>

  1. Kato R, Fukushima H, Kijima T, Yoshida S, Yokoyama M, Ishioka J, Matsuoka Y, Saito K, Otsuka Y, Koga F, Yano M, Tsukamoto T, Masuda H, Okuno T, Yonese J, Nagahama K, Kamata S, Noro A, Kageyama Y, Tsujii T, Morimoto S, Fujii Y. Predictive performance of the qSOFA score for in-hospital mortality of obstructive pyelonephritis patients: A multi-institutional study. The 35th Annual Congress of the European Association of Urology 2020 Amsterdam, Netherlands

  2. Yoshida S., Tanaka H, Kijima T., Yokoyama M., Ishioka J., Matsuoka Y., Saito K., Kihara K., Fujii Y.. Vesical Imaging-Reporting And Data System (VI-RADS) for bladder cancer staging with multiparametric MRI.. 113th annual meeting of the American Urological Association 2019.05.06 Chicago, USA.

  3. Matsuoka Y, Tanaka H,Kimura T, Moriyama S, Uehara S, Yasuda Y, Kijima T, Yoshida S, Yokoyama M,Ishioka J, Saito K, Fujii Y.. Usefulness of apparent diffusion coefficient ratio between tumor andnontumor as an imaging biomarker for prostate cancer.. The 114th annual meeting of the AmericanUrological Association, 2019.05.06 Chicago, USA

  4. Yoshida S. AUA/JUA International Affiliate Society Meeting 2019 Theme 1: Bladder cancer, Tri-Modality treatment for MIBC.. 113th annual meeting of the American Urological Association 2019.05.05 Chicago, USA.

  5. Yoshida S., Fukuda S., Moriyama S., Yokoyama M., Taniguchi N., Shinjo K., Sugimoto M., Saito K., Fujii Y.. Holographic surgical planning of partial nephrectomy using a wearable mixed reality computer. . 113th annual meeting of the American Urological Association 2019.05.04 Chicago, USA.

  6. Kijima T., Teramatsu R., Fukuda S., Fukushima H.,Moriyama S., Uehara S., Yasuda Y., Yoshida S., Yokoyama M., Ishioka J.Matsuoka Y., Saito K., Fujii Y. ,. High levels of heat-shock factor 1 (HSF1) are associated with poor prognosisin muscle-invasive bladder cancer patients treated with chemoradiation-basedbladder sparing protocol.. 113th annual meeting of the American　Urological Association 2019.05.04 Chicago, USA

  7. Fukushima H., Toide M., Fukuda S., Moriyama S., Yasuda Y., Uehara S., Kijima T., Yoshida S., Yokoyama M., Ishioka J., Matsuoka Y., Saito K., Fujii Y.. Impact of bladder neck involvement and positive urine cytology in substratifying intermediate-risk non-muscle-invasive bladder cancer patients based on the prediction of high-risk recurrence. . 113th annual meeting of the American Urological Association 2019.05.04 Chicago, USA

  8. Matsuoka Y, Uehara S, Yoshida S, Tanabe K, Tanaka H, Kimura T, Moriyama S,Yasuda Y, Kijima T, Yokoyama M, Ishioka J, Saito K, Fujii Y.. Who benefits additionally from concurrent systematic biopsy at the time ofMRI-ultrasound fusion targeted biopsy to detect significant prostate cancer?. The 114th　annual meeting of the American Urological Association 2019.05.04 Chicago,USA

  9. 木島敏樹, 森山真吾, 福田翔平, 上原翔, 安田庸輔, 吉田宗一郎横山みなと, 石岡準一郎, 松岡陽, 齋藤一隆, 木原和徳, 藤井靖久.，. 副腎皮質癌の治療成績：再発例に対する集学的治療（化学療法、放射線療法、再発巣切除）の有効性. . 第107回日本泌尿器科学会総会 2019.04.18 名古屋

  10. Kijima T., Teramatsu R., Fukuda S., Fukushima H.,Moriyama S., Uehara S., Yasuda Y., Yoshida S., Yokoyama M., Ishioka J.,Matsuoka Y., Saito K., Fujii Y.. High levels of heat-shock factor 1 (HSF1) are associated with poor prognosis in muscle-invasive bladder cancer patients treated with chemoradiation-based bladder sparing protocol. . The 34th Annual Congress of the EuropeanAssociation of Urology 2019.03.18 Barcelona, Spain

  11. Fukushima H., Saito K., Yasuda Y., Uehara S., Kijima T., Yoshida S., Yokoyama M., Ishioka J., Matsuoka Y., Kihara K., Koga F., Okuno T., Arisawa C., Kamata S., Nagahama K., Masuda H., Yonese J., Kageyama Y., Noro A., Tsujii T., Morimoto S., Fujii Y. . Obesity-specific effect of sex on prognosis of upper urinary tract urothelial carcinoma patients undergoing radical nephroureterectomy: A Japanese multicenter study. . The 34th Annual Congress of the European Association of Urology 2019.03.18 Barcelona, Spain

  12. Fukushima H., Kijima T., Toide M., Fukuda S., Moriyama S., Yasuda Y., Uehara S., Yoshida S., Yokoyama M., Ishioka J., Matsuoka Y., Saito K., Kihara K., Fujii Y.. Tetra-modality bladder sparing therapy can be a viable treatment option for muscle-invasive bladder cancer patients with sarcopenia. . The 34th Annual Congress of the European Association of Urology 2019.03.18 Barcelona, Spain

  13. Kasumi Kaneko, Soichiro Yoshida, Yuki Arita, Kouhei Yamamoto, Toshiki　Kijima, Minato Yokoyama, Junichiro Ishioka, Yoh Matsuoka, Kazutaka　Saito, Yasuhisa Fujii. Renal epithelioid angiomyolipoma: Incidence in a Japanese cohort and　diagnostic utility of diffusion-weighted MRI. The 34th Annual Congress of the European Association of Urology, 2019.03.17 Barcelona, Spain.

  14. Yoshida S., Fukuda S., Moriyama S., Yokoyama M., Taniguchi N., Shinjo K., Sugimoto M., Saito K., Fujii Y. . Holographic surgical planning of partial nephrectomy using a wearable mixed reality computer. . The 34th Annual Congress of the European Association of Urology 2019.03.17 Barcelona, Spain

  15. Yoshida S., Tanaka H, Kijima T., Yokoyama M., Ishioka J., Matsuoka Y., Saito K., Kihara K., Fujii Y.. Vesical Imaging-Reporting And Data System (VI-RADS) for bladder cancer staging with multiparametric MRI.. The 34th Annual Congress of the European Association of Urology 2019.03.17 Barcelona, Spain.

  16. Yoshida S., Takahara T., Ishii C., Nakagawa K., Toda K., Arita Y., Kijima T., Yokoyama M., Ishioka J., Matsuoka Y., Saito K., Yoshimura R., Fujii Y.. Loco-regional radiotherapy targeting oligo-progressive lesions in castration-resistant prostate cancer patients: Intra-pelvic localized progressive lesions are the good targets. . The 34th Annual Congress of the European Association of Urology 2019.03.17 Barcelona, Spain

  17. Kijima T., Fukuda S., Fukushima H., Moriyama S., Uehara S., Yasuda Y.,Yoshida S., Yokoyama M., Ishioka J., Matsuoka Y., Saito K., Fujii Y.. Clinical outcomes of muscle-invasive bladder cancer patients withhydronephrosis treated with tetramodality bladder sparing therapyincorporating consolidative partial cystectomy.　. The34th Annual Congress of the European Association of Urology, 2019.03.17 Barcelona, Spain

  18. Uchida Y., Yoshida S., ShimodaH., TanakaH., SakamotoT., UeharaS., YasudaY.,KijimaT., YokoyamaM., IshiokaJ., MatsuokaY., SaitoK., Fujii Y.. Differentiation of chromophobe renal cell carcinoma and renal oncocytomawith whole-lesion ADC analysis on diffusion-weighted MRI. The 34th Annual Congress of the European Association of Urology 2019.03.17 Barcelona, Spain.

  19. Fukushima H., Toide M., Fukuda S., Moriyama S., Yasuda Y., Uehara S., Kijima T., Yoshida S., Yokoyama M., Ishioka J., Matsuoka Y., Saito K., Fujii Y.. Substratification of intermediate-risk non-muscle-invasive bladder cancer based on the prediction of high-risk recurrence: Impact of bladder neck involvement and positive urine cytology. . The 34th Annual Congress of the European Association of Urology 2019.03.17 Barcelona, Spain

  20. Matsuoka Y, Uehara S, Yoshida S, tanabe K, Tanaka H, KimuraT, Moriyama S, Yasuda Y, Kijima T, Yokoyama M, Ishioka J, Saito K, Fujii Y.. Who gains additional benefits from systematic biopsy concurrently performedwith MRI-ultrasound fusion targeted biopsy in the detection of significantprostate cancer?. he 34th Annual Congress of the European Association of Urology, 2019.03.16 Barcelona, Spain

< PREV - NEXT >

To the head of this page.▲